🇺🇸 FDA

Company profile · Sponsor

KYOWA

KYOWA KIRIN AUSTRALIA PTY LTD

EC39668 · TGA pharma AU
Pipeline
3
Drugs
2
Patents
0

Quick answer

KYOWA (EC39668) is a pharma company. headquartered in AU. listed on TGA. NovaPharmaNews links 3 pipeline programs, 2 drugs, and 0 patents to this profile..

Company facts

Ticker EC39668
Exchange TGA
Company type pharma
Headquarters AU

Pipeline (3)

Search pipeline →

  1. POTELIGEO 4 mg/mL concentrate for solution for infusion

    KYOWA

    Mycosis fungoides/Sezary syndrome recurrent

    phase 2 small molecule active

    1 trial

  2. A First-in-Human Study of KK2223 in Participants with T-cell Non-Hodgkin Lymphoma

    KYOWA

    T-cell Non-Hodgkin Lymphoma, Cutaneous T-cell lymphoma (CTCL), Peripheral T-cell lymphoma (PTCL)

    phase 1 other active

    1 trial

  3. KK8123

    KYOWA

    X-linked hypophosphatemia.

    phase 1 small molecule active

    1 trial

Drugs (2)

Search drugs →

  1. burosumab

    CRYSVITA

    M05BX05

  2. mogamulizumab

    POTELIGEO

    L01XC25

Frequently asked questions

What is KYOWA?

KYOWA (EC39668) is a pharma company. headquartered in AU. listed on TGA. NovaPharmaNews links 3 pipeline programs, 2 drugs, and 0 patents to this profile..

What pipeline programs does KYOWA sponsor?

We track 3 ClinicalTrials.gov-linked programs for KYOWA, including POTELIGEO 4 mg/mL concentrate for solution for infusion and 2 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does KYOWA company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.